How to Become a STELFONTA® (tigilanol tiglate injection) SUPERSTAR: Part 3 of 4

Overview:

This is the third part of a four-part series. In this session, we will take an in-depth look at Stage 3 (tumor destruction) and Stage 4 (tumor site healing) of the STELFONTA® treatment protocol. We will explore real life cases to understand what to expect and learn how to manage the temporary wounds created once the tumor sloughs away. Lastly, we will look at the wound healing process which is unique to STELFONTA. Participants will gain valuable insights into the final stages of the treatment process and the outcomes they can expect.

Learning Objectives:

• Conduct a deep dive into Stage 3 (tumor destruction) and Stage 4 (tumor site healing) of the STELFONTA® treatment protocol.. 
• Analyze real-life case shares to illustrate the effectiveness and practical application of STELFONTA® treatment. 
• Understand the outcomes of tumor destruction and the healing process of the tumor site.  
• Enhance practical knowledge and skills for managing the final stages of STELFONTA® treatment in clinical practice.

IMPORTANT SAFETY INFORMATION
Accidental self-injection of STELFONTA® (tigilanol tiglate injection) may cause severe wound formation. To decrease the risk of accidental self-injection, sedation of the dog may be necessary. In dogs, do not inject STELFONTA into subcutaneous mast cell tumors located above the elbow or hock. Formation of wounds, possibly extensive, is an intended and likely response to treatment with STELFONTA along with associated swelling, bruising and pain; these wounds are expected to heal. Appropriate pre- and post-treatment medications must be given, including a corticosteroid plus blocking agents for both H1 and H2 receptors, in order to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation. For full prescribing information, contact VIRBAC at 1-800-338-3659 or visit https://vet-us.virbac.com/stelfonta.